Instructions for Clarithromycin extended release
English product name
Clarithromycin
Release Form
tab. film sheath, 500 mg: 7, 10, 14 or 20 pcs.
Description
The tablets are covered with a film shell of light yellow, oblong, double-convex; on the cross section the kernel is white or almost white.
1 tab.
clarithromycin 500 mg
Adjuvants: sodium croskarmellosis - 42.5 mg, microcrystalline cellulose - 222.5 mg, colloidal silicon dioxide - 25.5 mg, pregelatinized starch - 34 mg, stearic acid - 8.5 mg, stearyl fumarate sodium - 17 mg.
Envelope composition: VOVACOAT® PA-2P-097 - 47 mg (hypromellose (hydroxypropyl methylcellulose 6sPp) - 18.33 mg, titanium dioxide - 15.068 mg, polydextrose (E1200) - 7.05 mg, talc - 3.29 mg, macrogol 3350 (polyethylene glycol 3350) - 2.82 mg, dye quinoline yellow (E172) - 0.019 mg)
7 pcs. - packages of contour compartments (1) - cardboard packs.
7 pcs. - packages of contour compartments (2) - cardboard packages.
10 pcs. - packages of contour compartments (1) - cardboard packs.
10 pcs. - packages of contour compartments (2) - cardboard packages.
ATC codes
J01FA09 Clarithromycin
Clinical-pharmacological groups / Group affiliation
Macrolide group
Active substance
clarithromycin
Pharmaco-therapeutic group
macrolide
Pharmacological effect
A semi-synthetic of the macrolide group. It inhibits the synthesis of proteins in the microbial cell by interacting with the 50S ribosomal subunit of bacteria. It acts mainly bacteriostatically as well as bactericidically.
Active in Gram-positive aerobic microorganisms - Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumonia,
Testimony
- Treatment of infectious inflammatory diseases caused by clarithromycin-sensitive pathogens:
- upper respiratory tract and ENT organ infections (tonsillopharyngitis, middle otitis, acute sinusitis);
- lower respiratory tract infections (acute bronchitis,
- acute bronchitis, acute bronchitis,
- out-of-hospital bacterial and atypical pneumonia);
- odontogenic infections;
- skin and soft tissue infections; mycobacterial infections (M.avium complex, M.kansasii, M.marinum, M.leprae) and their
- prophylaxis in AIDS patients;
- eradication of Helicobacter pylori in patients with AIDS ulcerative disease of the duodenum or stomach (only in combination therapy).
Method of use, course and dosage
Individual. For adults and children over 12 years of age, a single dose is 0.25-1 g, twice daily.
For children under twelve years of age, the daily dose is 7.5-15 mg/kg/day in two doses.
In children, clarithromycin should be used in an appropriate form of medicine for this category of patients.
The duration of treatment depends on the indications.
Patients with kidney failure (QC less than 30 ml/min or serum creatinine levels greater than three.3 mg/dl) should reduce the
dose by half or double the interval between treatments.
Maximum daily dose: adult two g, children one g.
- Nosology (ICD codes)
- A31.0
- Pulmonary infection caused by Mycobacterium
- A48.1
- Legionnaires' disease
- B98.0
- Helicobacter pylori as the cause of diseases classified in other categories
- H66
- Pus and unspecified mean otitis
- J01
- Acute sinusitis
- J02
- Acute pharyngitis
- J03
- Acute tonsillitis
- J04
- Acute laryngitis and tracheitis
- J15
- Bacterial pneumonia not classified elsewhere
- J15.7
- Pneumonia caused by Mycoplasma pneumoniae
- J16.0
- Chlamydia-induced pneumonia
- J20
- Acute bronchitis
- J31.2
- Chronic pharyngitis
- J32
- Chronic sinusitis
- J35.0
- Chronic tonsillitis
- J37
- Chronic laryngitis and laryngotracheitis
- J42
- Chronic bronchitis unspecified
- K04
- Diseases of the pulp and periapical tissues (including periodontitis)
- K25
- Stomach ulcer
- K26
- Duodenum ulcer
- K27
- Peptic ulcer
- L01
- Impetigo
- L02
- Skin abscess, boils and carbuncles
- L03
- Phlegmona
- L08.0
- Piodermia
- L08.8
- Other Refined Local Skin and Subcutaneous Fibre Infections
- T79.3
- Post-traumatic wound infection not classified elsewhere
